- Home
- NRXP vs OTLK Comparison
NRXP vs OTLK Comparison
Compare NRXP & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- OTLK
- Stock Information
- Founded
- NRXP 2015
- OTLK 2010
- Country
- NRXP United States
- OTLK United States
- Employees
- NRXP N/A
- OTLK N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRXP Health Care
- OTLK Health Care
- Exchange
- NRXP Nasdaq
- OTLK Nasdaq
- Market Cap
- NRXP 58.5M
- OTLK 48.3M
- IPO Year
- NRXP N/A
- OTLK 2016
- Fundamental
- Price
- NRXP $3.05
- OTLK $1.02
- Analyst Decision
- NRXP Strong Buy
- OTLK Buy
- Analyst Count
- NRXP 5
- OTLK 5
- Target Price
- NRXP $31.40
- OTLK $8.50
- AVG Volume (30 Days)
- NRXP 498.6K
- OTLK 8.0M
- Earning Date
- NRXP 11-13-2025
- OTLK 08-14-2025
- Dividend Yield
- NRXP N/A
- OTLK N/A
- EPS Growth
- NRXP N/A
- OTLK N/A
- EPS
- NRXP N/A
- OTLK N/A
- Revenue
- NRXP N/A
- OTLK $1,505,322.00
- Revenue This Year
- NRXP N/A
- OTLK N/A
- Revenue Next Year
- NRXP $231.16
- OTLK $484.88
- P/E Ratio
- NRXP N/A
- OTLK N/A
- Revenue Growth
- NRXP N/A
- OTLK N/A
- 52 Week Low
- NRXP $1.10
- OTLK $0.79
- 52 Week High
- NRXP $6.01
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- NRXP 58.85
- OTLK 35.87
- Support Level
- NRXP $2.91
- OTLK $1.02
- Resistance Level
- NRXP $3.18
- OTLK $1.19
- Average True Range (ATR)
- NRXP 0.24
- OTLK 0.11
- MACD
- NRXP 0.04
- OTLK -0.00
- Stochastic Oscillator
- NRXP 87.19
- OTLK 50.13
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.